LLY
$1,281.91+0.22%
as of close, Oct 27, 2026
☾ AH $1,281.91 +0.22%
LLY — Eli Lilly and Company price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDED
200.0400.0600.0800.01000.01200.00200.0M$1281.91—20162019202120242026
2026-10-27
Price$1281.91
MA20$1164.88
MA50$1029.23
Vol8.9M
Key stats#
Price data
- Price
- $1,281.91
- YTD price return
- +19.28%
- YTD total return
- +19.86%
- Next earnings
- Oct 29, 2026 · Before open
- Market cap
- 1.1T
- Enterprise value
- 1.2T
- Shares outstanding
- 893.7M
- 52W low
- $809.63
- 52W high
- $1,321.21
- From 52W high
- -2.97%
- From 52W low
- +58.33%
- 52W range
- 92%
- Beta
- 0.50
Volume
- Rel volume
- 0.80×
- 30D volume
- 2.3M
- 30D $ vol
- 2.8B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$16.0M
- Insider net 1Y
- −$358.5M
Form 4 transactions by trade date, as filed; latest on file 2026-08-17.
Fundamentals
- Sales (ttm)
- 79.7B
- Sales/share
- $89.14
- EPS (ttm)
- $29.79
- FCF (ttm)
- 18.2B
- FCF/share
- $20.35
- Book value/share
- $37.91
- Net margin
- 33.53%
- ROE
- 78.84%
- ROA
- 18.77%
- Debt / equity
- 1.41×
- Current ratio
- 1.35
Growth (CAGR, ttm) · 10Y
- Sales
- +49.62%+39.22%+24.42%+14.48%
- Net income
- +93.65%+60.18%+34.50%+26.91%
- FCF
- +272.71%+69.75%+25.99%+24.02%
- Shares
- -0.68%-0.33%-0.37%-1.69%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +94.84%+60.60%+34.96%+29.08%
- Sales/share
- +50.64%+39.69%+24.88%+16.45%
- FCF/share
- +275.25%+70.32%+26.51%+26.57%
- Book value/share
- +86.75%+45.69%+39.89%+10.63%
- Dividend/share
- +15.36%+15.25%+10.67%+12.72%
- Price
- +55.16%+31.77%+38.66%+32.51%
- Total return
- +56.14%+32.67%+39.92%+34.60%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 43.0×
- Fwd P/E
- 27.0×
- P/S (ttm)
- 14.4×
- P/B (mrq)
- 33.8×
- P/FCF (ttm)
- 63.0×
- EV/Sales (ttm)
- 15.0×
- FCF yield (ttm)
- 1.59%
- Dividend yield (fwd)
- 0.54%
- Dividend yield (ttm)
- 0.52%
- Dividend/share (fwd)
- $6.92
- Buyback yield (cash, ttm)
- 0.54%
- Shareholder yield (cash, ttm)
- 1.04%
Vs own 10Y history
- P/E
- 54th
- P/S
- 80th
- P/B
- 58th
- P/FCF
- 48th
Bar = where today’s multiple sits in LLY’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+0.22%
5D
-0.14%
1M
+8.32%
3M
+7.05%
YTD
+19.28%
1Y
+55.12%
5Y
+412.42%
Recent filings#
- Aug 5Earnings · Earnings release — EPS $8.38 vs $6.01 est. (+39.4%); revenue $22.97B (+48% y/y) 4.9%
Financial statements
Open full LLY financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
| GILD | Gilead Sciences Inc. | +5.40% | +0.25% |
